On November 18, 2021, CSPC Pharmaceutical Group (01093.HK) announced that for the nine months ended September 30, 2021, the company achieved total revenue of RMB20.642 billion (the same unit below), an increase of 7.4% year-on-year; gross profit of RMB15.655 billion, an increase of 8.3% year-on-year; profit attributable to shareholders of RMB4.335 billion, an increase of 23.2% year-on-year; and basic earnings per share of 36.26 cents.
Ready-to-use business
During the period, the Group continued to adopt strategies such as professional academic promotion, hospital development, market sinking, clinical application scope expansion, and professional sales force expansion to promote the growth of key proprietary medicine products and promote the market layout of different levels of medical institutions from cities to counties, townships and communities. The proprietary medicine business recorded revenue of MOP16,802 million during the period, an increase of 6.9% over the same period last year.
Neurological disease products: The main products include Embip (butanphthalide softgels and butanphthalide sodium chloride injection), Oline (Oxiracetam capsules and Oxiracetam for injection), Shu'anling (pentoxifyl anthradine extended-release tablets and hexanone cocoa alkali injection), Enxi (pramipexole hydrochloride tablets) and Oleto (memantine hydrochloride tablets). During the Period, sales revenue of neurological disease products was RMB5.505 billion. Since March, Enbipu has been marketing at the negotiated price of the new national health insurance, and the accessibility and competitiveness of the products have been greatly improved. The Group uses the wide coverage of products, the deep sinking market base, and the expansion of the self-funded market of Internet hospitals to achieve rapid sales growth and greatly digest the impact of price reductions.
Anti-tumor products: The main products include dormecil (doxorubicin hydrochloride liposome injection), Jinyouli (polyethylene glycolated recombinant human granulocyte stimulating factor injection), cretil (paclitaxel for injection (albumin-binding type)) and Wanda (bortezomib for injection). During the Period, anti-tumor products recorded sales revenue of RMB5.778 billion, an increase of 22.5% year-on-year, of which the sales revenue of Dormesole, Keali and Jinyouli increased by 33.0%, 25.3% and 6.8% respectively.
Anti-infective products: The main products include Shurok (meropenem for injection), nomorin (amoxicillin capsules), Xianqu/Lithoto (ceftriaxone sodium for injection), Zhongnuo Lixin (cefuroxime sodium for injection), neovitron (azithromycin tablets), Weihong (azithromycin dispersible tablets/capsules/enteric-coated tablets). During the Period, anti-infective products recorded sales revenue of RMB2,115 million, an increase of 3.5% year-on-year.
Cardiovascular disease products: The main products include Xuan Ning (levlodipine maleate tablets and dispersible tablets), Encun (clopidogrel bisulfate tablets), Dacinin (dronedarone hydrochloride tablets), Abicone (aspirin enteric-coated tablets) and mellon (tigrelor tablets). During the Period, sales revenue of cardiovascular disease products recorded a sales revenue of RMB2,127 million, an increase of 20.7% year-on-year, of which the sales revenue of Xuanning and Encun increased by 18.5% and 29.3% respectively.
Respiratory disease products: The main products include Qi gong (Abidole hydrochloride tablets), Zhongnuo Lik (oral solution of ambroxol hydrochloride), Zhongnuoping (ambroxol hydrochloride extended-release tablets) and Neuyoan (montelukast sodium tablets/chewable tablets). During the Period, respiratory disease products recorded sales revenue of $276 million.
Digestive and metabolic disease products: The main products include Lin Meixin (glimepiride dispersible tablets), shuanglexin (metformin hydrochloride tablets/extended-release tablets), xinweiping (acarbose tablets) and debixin (omeprazole enteric-coated capsules). During the Period, products with digestive and metabolic diseases recorded sales revenue of RMB398 million, an increase of 5.5% year-on-year.
Other therapeutic products: Major products include Gubang (alendronate tablets/enteric-coated tablets), chimet (tramadol hydrochloride tablets) and yodenine (celecoxib capsules). During the Period, sales revenue of products in other therapeutic areas was RMB554 million, an increase of 17.1% year-on-year.
Raw material products business
Mainly driven by higher product prices, vitamin C products recorded sales revenue of $1,617 million during the period, an increase of 12.4% over the same period last year. Sales revenue from antibiotics and other products also increased by 24.0% to MOP1,235 million due to higher sales volumes.
Functional foods and other businesses
The business recorded sales revenue of $988 million during the Period.
This article originated from Grand Gateway
![Deserved! Sun Zhuo's sister Sun Yue returned to Shenzhen to teach, and the top three teaching schools were strong[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)